During metastasis, cancer cells invade, intravasate, enter the circulation, extravasate, and colonize target organs. Here, we examined the role of interleukin (IL)-22 in metastasis. Immune cell-derived IL-22 acts on epithelial tissues, promoting regeneration and healing upon tissue damage, but it is also associated with malignancy. Il22-deficient mice and mice treated with an IL-22 antibody were protected from colon-cancer-derived liver and lung metastasis formation, while overexpression of IL-22 promoted metastasis. Mechanistically, IL-22 acted on endothelial cells, promoting endothelial permeability and cancer cell transmigration via induction of endothelial aminopeptidase N. Multi-parameter flow cytometry and single-cell sequencing of immune cells isolated during cancer cell extravasation into the liver revealed iNKT17 cells as source of IL-22. iNKT-cell-deficient mice exhibited reduced metastases, which was reversed by injection of wild type, but not Il22-deficient, invariant natural killer T (iNKT) cells. IL-22-producing iNKT cells promoting metastasis were tissue resident, as demonstrated by parabiosis. Thus, IL-22 may present a therapeutic target for prevention of metastasis.
Institut(e)Unit for Clinical Pharmacology (KKG-EKLiP)
FörderungenEuropean Research Council Else Kroner Memorial Stipendium Erich und Gertrud Roggenbuck-Stiftung Hamburger Krebsgesellschaft Stiftung Jung Foundation for Science and Research Howard Hughes Medical Institute Alexander von Humboldt Stiftung for an Experienced Researcher Fellowship AIRC European Union Deutsche Forschungsgemeinschaft (DFG) Deutsche Krebshilfe ERC Advanced Investigator Grant